Terms ending in 2027
Every in-force patent on Ucb Pharma S.A.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,604,051 | Thieno-Pyridine Derivatives as Mek Inhibitors In force · Medium confidence | Ucb Pharma S.A. | In force | Medium confidence | |
| US D676,552 | Needle Cap for a Medication Administration Device In force · High confidence | Ucb Biopharma SPRL | In force | High confidence | |
| US 9,309,215 | Chiral Intermediate, Process for Producing the Same and Its Use in the Manufacture of Tolterodine, Fesoterodine, or the Active Metabolite Thereof In force · Low confidence | Ucb Pharma GmbH | In force | Low confidence | |
| US 7,807,715 | Pharmaceutical Compositions Comprising Fesoterodine In force · High confidence | Ucb Pharma GmbH | In force | High confidence | |
| US 9,364,541 | Pharmaceutical Compositions Comprising Fesoterodine In force · Medium confidence | Ucb Pharma GmbH | In force | Medium confidence | |
| US 9,095,557 | Anticonvulsant Combination Therapy In force · Medium confidence | Ucb Pharma GmbH | In force | Medium confidence | |
| US 9,446,011 | Anticonvulsant Combination Therapy In force · High confidence | Ucb Pharma GmbH | In force | High confidence | |
| US 7,888,344 | Fused Thiazole Derivatives as Kinase Inhibitors In force · High confidence | Ucb Biopharma SPRL | In force | High confidence | |
| US 7,982,058 | Chiral Intermediate, Process for Producing the Same and Its Use in the Manufacture of Tolterodine, Fesoterodine, or the Active Metabolite Thereof In force · High confidence | Ucb Pharma GmbH | In force | High confidence | |
| US 8,633,194 | Pharmaceutical Composition Of Piperazine Derivatives In force · High confidence | Ucb Biopharma SPRL | In force | High confidence | |
| 5 more term ends in 2027 · Pro | |||||
10 of 15 patents shown. Soonest term end first, then patent number.
Pro members see all 15, all of them expiring within the 18 months from Nov 21, 2026.
9 of these are in force and held by Ucb Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.